Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraperitoneal delivery of the oncolytic virus CF17 improves tumor immunogenicity and survival in gastric cancer peritoneal metastasis.

Molecular therapy. Oncology·2026
Same author

Regulating Electron-Density Distribution of Pyridine Derivative Passivators for Efficient Carbon-Based CsPbI<sub>3-x</sub>Br<sub><i>x</i></sub> Perovskite Solar Cells.

The journal of physical chemistry letters·2026
Same author

Biodegradation of polyvinyl chloride (PVC) microplastics in superworms (Zophobas atratus larvae): High biodegradation rate with limited mineralization and elevation of oxidative stress.

Insect science·2026
Same author

Independent Motion Segmentation Based on Pure Event Data.

Sensors (Basel, Switzerland)·2026
Same author

The identification of genes related to METTL14 inhibition in radiation-induced hepatocyte death based on bioinformatics analysis.

Scientific reports·2026
Same author

Flavonoids as Inhibitors of VEGFR2 Signaling: Structural Insights for the Development of Safer Anti-Angiogenic Therapies.

International journal of molecular sciences·2026

Related Experiment Video

Updated: May 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

SLC15A2 Serves as a Novel Prognostic Biomarker and Target for Prostate Cancer.

Wenjun Yin1,2, Pingkaiqi He1, Zhihao Zou2,3

  • 1Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou, P.R. China.

Anticancer Research
|December 31, 2024
PubMed
Summary

Solute carrier family 15 member 2 (SLC15A2) is a promising prognostic biomarker for prostate cancer (PCa). Reduced SLC15A2 expression correlates with poor outcomes, offering potential for risk stratification and personalized PCa treatments.

Keywords:
SLC15A2biochemical recurrenceprognostic biomarkerprostate cancer

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

977

Related Experiment Videos

Last Updated: May 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

977

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Solute carrier family 15 member 2 (SLC15A2) plays a role in cellular signaling but its function in prostate cancer (PCa) is unclear.
  • Investigating SLC15A2's prognostic value is crucial for understanding PCa progression.

Purpose of the Study:

  • To determine the prognostic significance of SLC15A2 in prostate cancer (PCa).
  • To explore the biological functions and therapeutic targeting of SLC15A2 in PCa.

Main Methods:

  • Multicenter cohort analysis of SLC15A2 expression and survival in PCa patients.
  • In vitro validation, gene set enrichment, mutation, methylation, and drug target prediction analyses were performed.

Main Results:

  • SLC15A2 expression is significantly lower in PCa tissues and linked to reduced survival and increased recurrence.
  • SLC15A2 knockdown enhances PCa cell proliferation and migration; its downregulation is associated with TP53 mutations and DNA hypermethylation.
  • Rucaparib identified as a potential therapeutic agent targeting SLC15A2 in PCa.

Conclusions:

  • SLC15A2 is a valuable prognostic biomarker for PCa, aiding in biochemical recurrence risk stratification.
  • Findings support the development of personalized treatment strategies for PCa based on SLC15A2 status.